Top

Journal of Orthopaedic Science

Published in:

01-07-2014 | Original Article

Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats

Authors: Deepak Kumar Khajuria, Rema Razdan, Debiprosad Roy Mahapatra

Published in: Journal of Orthopaedic Science | Issue 4/2014

Abstract

Background

We conducted the present study to investigate the therapeutic effects of the antiresorptive agent zoledronic acid (ZOL), alone and in combination with alfacalcidol (ALF), in a rat model of postmenopausal osteoporosis.

Methods

Female Wistar rats were ovariectomized (OVX) or sham-operated at 3 months of age. Twelve weeks post surgery, rats were randomized into six groups: (1) sham + vehicle, (2) OVX + vehicle, (3) OVX + ZOL (100 μg/kg, i.v. single dose), (4) OVX + ZOL (50 μg/kg, i.v. single dose), (5) OVX + ALF (0.5 μg/kg, oral gauge daily) and (6) OVX + ZOL (50 μg/kg, i.v. single dose) + ALF (0.5 μg/kg, oral gauge daily) for 12 weeks. After treatment, we evaluated the mechanical properties of the lumbar vertebra and femoral mid-shaft. Femurs were also tested for bone density, porosity and trabecular micro-architecture. Biochemical markers in serum and urine were also determined.

Results

With respect to improvement in the mechanical strength of the lumbar spine and the femoral mid-shaft, the combination treatment of ZOL and ALF was more effective than each administered as a monotherapy. Moreover, combination therapy using ZOL and ALF preserved the trabecular micro-architecture and cortical bone porosity. Furthermore, the combination treatment of ZOL and ALF corrected the decrease in serum calcium and increase in serum alkaline phosphatase and the tartarate-resistant acid phosphatase level better than single-drug therapy using ZOL or ALF in OVX rats. In addition, the combination treatment of ZOL and ALF corrected the increase in urine calcium, phosphorous and creatinine levels better than single-drug therapy using ZOL or ALF in OVX rats.

Conclusions

These data suggest that the combination treatment of ZOL and ALF has a therapeutic advantage over each monotherapy for the treatment of osteoporosis.

Khajuria DK, Razdan R, Mahapatra DR. Drugs for the management of osteoporosis: a review. Rev Bras Reumatol. 2011;51:365–82.PubMedCrossRef

Hohenhaus MH, McGarry KA, Col NF. Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option? Drugs. 2007;67:2311–21.PubMedCrossRef

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.PubMedCrossRef

Coxon FP, Helfrich MH, Van’t Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15:1467–76.PubMedCrossRef

Nielson OS, Munro AJ, Tannock IF. Bone metastasis: pathophysiology and management policy. J Clin Oncol. 1991;9:509–24.

Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28:465–73.PubMedCrossRef

Khajuria DK, Razdan R, Mahapatra DR, Bhat MR. Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol. J Orthop Sci. 2013;18:832–42.PubMedCrossRef

Khajuria DK, Disha C, Razdan R, Mahapatra DR. Comparative evaluation of zoledronic acid, alfacalcidol, and propranolol in pharmacological correction of experimental osteoporosis. Lat Am J Pharm. 2013;32:968–76.

Khajuria DK, Disha C, Razdan R, Mahapatra DR, Vasireddi R. Prophylactic effects of propranolol versus standard therapy on a new model of disuse osteoporosis in rats. Sci Pharm. 2014. doi:10.3797/scipharm.1310-06.

10.

Izawa Y, Makita T, Hino S, Hashimoto Y, Kushida K, Inoue T, Orimo H. Immobilization osteoporosis and active vitamin D: effect of active vitamin D analogs on the development of immobilization osteoporosis in rats. Calcif Tissue Int. 1981;33:623–30.PubMedCrossRef

11.

Ringe JD. Combination treatment in osteoporosis. Basic treatment plus specific osteoporosis medication. Med Monatsschr Pharm. 2009;32:137–40.PubMed

12.

Sasaki H, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Kamo K, Shimada Y. Effects of combination treatment with alendronate and vitamin K (2) on bone mineral density and strength in ovariectomized mice. J Bone Miner Metab. 2010;28:403–9.PubMedCrossRef

13.

Sakai S, Endo K, Takeda S, Mihara M, Shiraishi A. Combination therapy with alendronate and eldecalcitol has therapeutic advantages over monotherapy by improving bone strength. Bone. 2012;50:1054–63.PubMedCrossRef

14.

Schacht E, Dukas L, Richy F. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Musculoskelet Neuronal Interact. 2007;7:174–84.PubMed

15.

Ringe JD, Farahmand P, Schacht E, Rozehnal A. Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int. 2007;27:425–34.PubMedCrossRef

16.

Erben RG, Mosekilde L, Thomsen JS, Weber K, Stahr K, Leyshon A, Smith SY, Phipps R. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1α,25-dihydroxyvitamin D3. J Bone Miner Res. 2002;17:1498–511.PubMedCrossRef

17.

Khajuria DK, Razdan R, Mahapatra DR. Description of a new method of ovariectomy in female rats. Rev Bras Reumatol. 2012;52:466–70.CrossRef

18.

Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem. 2001;47:74–80.PubMed

19.

Riis BJ. The role of bone turnover in the pathophysiology of osteoporosis. Br J Obstet Gynaecol. 1996;103(Suppl. 13):9–15.PubMed

20.

Christiansen C, Riss BJ, Rodbro P. Screening procedure for women at risk of developing post menopausal osteoporosis. Osteoporos Int. 1990;1:35–40.PubMedCrossRef

21.

Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis. Br Med J. 1991;303:961–4.CrossRef

22.

Qureshi HJ, Hussain G, Jafary ZA, Bashir MU, Latif N, Riaz Z. Calcium status in premenopausal and postmenopausal women. J Ayub Med Coll Abbottabad. 2010;22:143–5.PubMed

23.

Yogesh HS, Chandrashekhar VM, Katti HR, Ganapaty S, Raghavendra HL, Gowda GK, Goplakhrishna B. Anti-osteoporotic activity of aqueous-methanol extract of Berberis aristata in ovariectomized rats. J Ethnopharmacol. 2011;134:334–8.PubMedCrossRef

24.

Kalu DK, Liu CC, Salerno E. Skeletal response of ovariectomized rats to low and high doses of 17β-estradiol. Bone Miner. 1991;1991(14):175–87.

25.

Das AS, Mukherjee M, Mitra C. Evidence for a prospective anti-osteoporosis effect of black tea (Camellia sinensis) extract in a bilaterally ovariectomized rat model. Asia Pac J Clin Nutr. 2004;13(2):210–6.PubMed

26.

Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J Bone Miner Res. 2009;24:209–20.PubMedCentralPubMed

27.

Papapetrou PD. Bisphosphonate-associated adverse events. Hormones. 2009;8:96–110.PubMedCrossRef

Title: Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats
Authors: Deepak Kumar Khajuria
Rema Razdan
Debiprosad Roy Mahapatra
Publication date: 01-07-2014
Publisher: Springer Japan
Published in: Journal of Orthopaedic Science / Issue 4/2014
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-014-0557-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

Translational research of herniated discs: current status of diagnosis and treatment

Comment on Matsumura et al.: changes in water content of intervertebral discs and paravertebral muscles before and after bed rest

Prevention of pin tract infection with iodine-supported titanium pins

Radiolucent zone of the patella following total knee arthroplasty without patellar resurfacing

Determination of the optimal cutoff time to use when screening elderly people for locomotive syndrome using the one-leg standing test (with eyes open)

Effect of neck length on third-generation ceramic head failure; finite element and retrieval analysis